Literature DB >> 25183093

Evaluation of immuno efficiency of hemorrhagic septicemia vaccine strain (vaccine seed).

Maheswarappa Gowrakkal1, M Chandrashekar2, Shankarappa Bhajantri2, Jaykumar Satav1, Gc Chandakala1, Asha Mayanna1, Sm Byregowda1, C Renukaprasad1.   

Abstract

OBJECTIVE: To compared seed culture of hemorrhagic septicemia (HS) bacteria which was used to produce vaccine for its antibody induction efficiency before and after passaging in natural host (calf) using laboratory animals.
METHODS: Serial dilution of virulent bacteria was injected in to mice which were immunized with HS vaccine which was obtained from seed bacteria before and after back passaged in calf. Ratio of survived and dead was calculated by Reed-Meunch hypothesis and the LD50 value for each vaccine trial groups were calculated.
RESULTS: The immunological study revealed that vaccine prepared from back passaged seed culture showed greater improvement in its immunopotency than seed vaccine (before back passage). Around 200 mice were used to study the immuno efficiency of vaccine. Each mouse was from the same source, which were free from the Pastuerella infection previous to expose to trial infection. The same broth culture of HS was used to induce infection in mice in both trials (vaccine before back passage and vaccine after back passage). The 0.2 mL of broth dilution from 10(-1) to 10(-10) was used, as dilution increases, death rate decreases. It indicates the minimum load of bacterium is required to induced infection.
CONCLUSIONS: Obtained results revealed that back passaged vaccine seed HS bacteria in its natural host had provided better immune efficiency to the culture than laboratory stock culture, and this findings recommended that regular annual back passage was mandatory for the vaccine seed culture of Pastuerella multocida bacteria for better establishment of immune potent vaccines.

Entities:  

Keywords:  Annual vaccination; Hemorrhagic septicemia; LD50 values; Laboratory animals; Natural host

Year:  2014        PMID: 25183093      PMCID: PMC4025304          DOI: 10.12980/APJTB.4.2014C554

Source DB:  PubMed          Journal:  Asian Pac J Trop Biomed        ISSN: 2221-1691


  5 in total

Review 1.  A review of hemorrhagic septicemia in cattle and buffalo.

Authors:  S B Shivachandra; K N Viswas; A A Kumar
Journal:  Anim Health Res Rev       Date:  2011-06       Impact factor: 2.615

2.  Vaccination of American bison against Pasteurella multocida serotype 2 infection (Hemorrhagic septicemia).

Authors:  K L Heddleston; G Wessman
Journal:  J Wildl Dis       Date:  1973-10       Impact factor: 1.535

3.  Efficacy of vaccination of calves against hemorrhagic septicemia with a live aroA derivative of Pasteurella multocida B:2 by two different routes of administration.

Authors:  J Christopher Hodgson; Anna Finucane; Mark P Dagleish; Saeed Ataei; Roger Parton; John G Coote
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

4.  Immunogenicity of outer membrane protein of Pasteurella multocida in buffalo calves.

Authors:  U S Pati; S K Srivastava; S C Roy; T More
Journal:  Vet Microbiol       Date:  1996-10       Impact factor: 3.293

Review 5.  Haemorrhagic septicaemia vaccines.

Authors:  R Verma; T N Jaiswal
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

  5 in total
  2 in total

1.  Efficacy of bacteriophage Lysed Pasteurella marker vaccine in laboratory animal models with a novel DIVA for haemorrhagic septicaemia.

Authors:  Sabia Qureshi; Hari Mohan Saxena
Journal:  Saudi J Biol Sci       Date:  2017-05-05       Impact factor: 4.219

Review 2.  Spatial, Temporal, and Demographic Patterns in the Prevalence of Hemorrhagic Septicemia in 41 Countries in 2005-2019: A Systematic Analysis with Special Focus on the Potential Development of a New-Generation Vaccine.

Authors:  Reyad Almoheer; Mohd Effendy Abd Wahid; Hidayatul Aini Zakaria; Mohd Anuar Bin Jonet; Muhanna Mohammed Al-Shaibani; Adel Al-Gheethi; Siti Nor Khadijah Addis
Journal:  Vaccines (Basel)       Date:  2022-02-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.